natgillin/translations-raw huggingface dataset:
This means that Accofil is similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU). 
To pomeni, da je zdravilo Accofil podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
Data from published studies indicate that the benefits and safety of filgrastim are similar in both adults and children receiving chemotherapy. 
Podatki iz objavljenih študij kažejo, da so koristi in varnost filgrastima podobne tako pri odraslih kot pri otrocih, ki prejemajo kemoterapijo.
This is a summary of the European public assessment report (EPAR) for Accofil. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Accofil.
It can only be obtained with a prescription and treatment should be given in collaboration with a centre for cancer treatment. 
Izdaja zdravila je le na recept, zdravljenje pa se lahko predpiše samo v sodelovanju s centrom za zdravljenje raka.
It is given by injection under the skin or infusion into a vein. 
Zdravilo se daje z injekcijo pod kožo ali infuzijo v veno.
A risk management plan has been developed to ensure that Accofil is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Accofil je bil pripravljen načrt obvladovanja tveganj.
Patients were given the chemotherapy on day 1 of a three-week cycle, and then received one dose of Accofil the next day and daily for up to 14 days. 
Bolnice so 1. dan tritedenskega ciklusa prejele kemoterapijo, naslednji dan pa so prejele en odmerek zdravila Accofil, ki so ga nato vsak dan prejemale še največ 14 dni.
The most common side effect with Accofil (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). 
Najpogostejši neželeni učinek zdravila Accofil (opaženi pri več kot 1 bolniku od 10) so mišično-skeletne bolečine (bolečine v mišicah in kosteh).
The way Accofil is given, its dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment. 
Način dajanja zdravila Accofil, velikost odmerka in trajanje zdravljenja so odvisni od tega, zakaj se zdravilo uporablja, ter od telesne mase bolnika in njegovega odziva na zdravljenje.
Other information about Accofil 
Druge informacije o zdravilu Accofil
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Accofil has been shown to have a comparable quality, safety and efficacy profile to Neupogen. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami Evropske unije za podobna biološka zdravila dokazano, da ima zdravilo Accofil podoben profil kakovosti, varnosti in učinkovitosti kot zdravilo Neupogen.
It is not intended to provide practical advice on how to use Accofil. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Accofil is a medicine that is used to stimulate the production of white blood cells in the following situations: 
Zdravilo Accofil se uporablja za spodbujanje tvorbe belih krvnih celic v naslednjih primerih:
Accofil was studied in one main study involving 120 female adult patients with breast cancer treated with chemotherapy known to cause neutropenia. 
Zdravilo Accofil so proučili v eni glavni študiji, v katero so vključili 120 odraslih bolnic z rakom dojke, ki so se zdravile s kemoterapijo, za katero je znano, da povzroča nevtropenijo.
What are the risks associated with Accofil? 
Kakšna tveganja so povezana z zdravilom Accofil?
What benefits of Accofil have been shown in studies? 
Kakšne koristi je zdravilo Accofil izkazalo v študijah?
For the full list of all side effects and restrictions reported with Accofil, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Accofil, glejte navodilo za uporabo.
The reference medicine for Accofil is Neupogen. 
Referenčno zdravilo za zdravilo Accofil je Neupogen.
The filgrastim in Accofil is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim. 
Filgrastim v zdravilu Accofil se pridobiva z metodo, imenovano „tehnologija rekombinantne DNK“: izdelajo ga bakterije, v katere so vstavili gen (DNK), s pomočjo katerega lahko tvorijo filgrastim.
What is Accofil and what is it used for? 
Kaj je zdravilo Accofil in za kaj se uporablja?
• to help release cells from the bone marrow in patients who are about to donate blood stem cells for transplant; 
• za pospeševanje sproščanja celic iz kostnega mozga pri bolnikih, ki naj bi darovali krvotvorne matične celice za presaditev;
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Accofil, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Filgrastim acts in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells. 
Filgrastim deluje na enak način kot naravno tvorjeni G-CSF, kar pomeni, da spodbuja kostni mozeg k tvorjenju večjega števila belih krvnih celic.
The active substance in Accofil, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF). 
Zdravilna učinkovina v zdravilu Accofil, filgrastim, je zelo podobna človeški beljakovini, ki jo imenujemo granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G-CSF).
More information can be found in the summary of product characteristics (also part of the EPAR). 
Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risks and recommended that it be approved for use in the EU. 
Zato je menil, da so njegove koristi, tako kot pri zdravilu Neupogen, večje od znanih tveganj, in priporočil, da se odobri za uporabo v EU.
Studies were carried out to show that Accofil produces similar levels of the active substance in the body to Neupogen and increases the numbers of neutrophils in a comparable way. 
Izvedene so bile študije, v katerih so dokazovali, da zdravilo Accofil tvori podobne ravni zdravilne učinkovine v telesu kot zdravilo Neupogen in da poveča število nevtrofilcev na primerljiv način.
• to treat persistent neutropenia in patients with advanced Human-Immunodeficiency-Virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate. 
• za zdravljenje trdovratne nevtropenije pri bolnikih z napredovalo okužbo z virusom humane imunske pomanjkljivosti (HIV), z namenom zmanjšanja tveganja za bakterijske okužbe, ko druge oblike zdravljenja niso primerne.
Other side effects may be seen in more than 1 patient in 10, depending on the condition that Accofil is being used for. 
Pri več kot 1 bolniku od 10 se lahko pojavijo drugi neželeni učinki, ki so odvisni od bolezenskega stanja, za katerega se zdravilo Accofil uporablja.
For more information about treatment with Accofil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Accofil preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Accofil is available as a solution for injection or infusion (drip) in pre-filled syringes. 
Zdravilo Accofil je na voljo v obliki raztopine za injiciranje ali infundiranje (kapalno infuzijo) v napolnjenih injekcijskih brizgah.
For practical information about using Accofil, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Accofil naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
• to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving cytotoxic chemotherapy (medicines to treat cancer by killing cells); 
• za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, ki so vrsta belih krvnih celic) in zmanjšanje pojavljanja febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo citotoksično kemoterapijo (zdravila za zdravljenje raka, ki ubijajo celice);
Accofil, which contains the active substance filgrastim, is a ‘biosimilar medicine'. 
Zdravilo Accofil, ki vsebuje zdravilno učinkovino filgrastim, je „biološko podobno“ zdravilo.
• to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections; 
• za povečanje števila nevtrofilcev in zmanjšanje tveganja za okužbe pri bolnikih z nevtropenijo, ki so imeli v preteklosti hude ponavljajoče se okužbe;
Why is Accofil approved? 
Za kaj je bilo zdravilo Accofil odobreno?
• to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at risk of long-term, severe neutropenia; 
• za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dalj časa trajajočo hudo nevtropenijo;
How is Accofil used? 
Kako se zdravilo Accofil uporablja?
How does Accofil work? 
Kako zdravilo Accofil deluje?
10 (2 x 5) pre-filled pens (multipack) 
10 (2 x 5) napolnjenih injekcijskih peresnikov (multipakiranje)
Content (concentration) Package size 
Vsebina (koncentracija)
Invented name Strength Pharmaceutical form Route of administration Packaging 
Izmišljeno ime Jakost
Powder: 1000 IU 
Pot uporabe Ovojnina
Further information on Carmustine Obvius can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu Karmustin Obvius so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The medicine is used when initial treatment has not worked or the cancer has come back. 
Zdravilo se uporablja, kadar začetno zdravljenje ni delovalo ali se je rak ponovil.
Carmustine Obvius (carmustine) EMA/273425/2018 
Karmustin Obvius (karmustin) EMA/273425/2018
• Hodgkin's lymphoma and non-Hodgkin's lymphomas, types of cancer that originate from white blood cells. 
• Hodgkinovega limfoma in ne-Hodgkinovih limfomov, tj. vrst raka, ki izvirajo iz belih krvnih celic.
• brain tumours, both those that develop directly in the brain and cancers that have spread from elsewhere in the body (metastatic brain tumours); 
• možganskih tumorjev, in sicer tistih, ki se razvijejo neposredno v možganih, in rakov, ki so se razširili z drugih delov telesa (metastatskih možganskih tumorjev);
It interferes with the normal function and repair of DNA and RNA, the genetic instructions that cells need to function and multiply. 
Ovira normalno delovanje in popravljanje DNK in RNK, tj. genetskih navodil, ki jih celice potrebujejo za delovanje in podvajanje.
A dose based on the patient's weight and height is given at intervals of at least 6 weeks, and should be adjusted according to the patient's blood cell counts. 
Odmerek, ki temelji na bolnikovi telesni masi in višini, se daje v vsaj šesttedenskih presledkih in ga je treba prilagoditi glede na bolnikovo krvno sliko.
The European Medicines Agency concluded that, in accordance with EU requirements, Carmustine Obvius has been shown to be comparable to Carmubris. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Karmustin Obvius primerljivo z zdravilom Carmubris.
What measures are being taken to ensure the safe and effective use of Carmustine Obvius? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Karmustin Obvius?
Carmustine Obvius is a cancer medicine that is used, on its own or with other cancer medicines and treatments, to treat the following types of cancer: 
Karmustin Obvius je zdravilo proti raku, ki se uporablja samostojno ali skupaj z drugimi zdravili in zdravljenji za zdravljenje naslednjih vrst raka:
Because Carmustine Obvius is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Karmustin Obvius generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
As for every medicine, the company provided studies on the quality of Carmustine Obvius. 
Tako kot za vsako zdravilo je družba predložila študije o kakovosti zdravila Karmustin Obvius.
An overview of Carmustine Obvius and why it is authorised in the EU 
Pregled zdravila Karmustin Obvius in zakaj je odobreno v EU
Studies on the benefits and risks of the active substance carmustine in the authorised uses have already been carried out with the reference medicine, Carmubris, and do not need to be repeated for Carmustine Obvius. 
Študije o koristih in tveganjih učinkovine karmustina pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Carmubris, zato jih ni treba ponoviti za zdravilo Karmustin Obvius.
Other information about Carmustine Obvius 
Druge informacije o zdravilu Karmustin Obvius
What are the benefits and risks of Carmustine Obvius? 
Kakšne so koristi in tveganja zdravila Karmustin Obvius?
Carmustine Obvius (carmustine) 
Karmustin Obvius (karmustin)
What is Carmustine Obvius and what is it used for? 
Kaj je zdravilo Karmustin Obvius in za kaj se uporablja?
Carmustine Obvius is a ‘generic medicine'. 
Zdravilo Karmustin Obvius je „generično zdravilo“.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Carmustine Obvius have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Karmustin Obvius upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
This means that Carmustine Obvius contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Carmubris. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Carmubris.
By damaging the DNA of cancer cells, carmustine can help kill them and prevent the cancer from growing and spreading. 
Karmustin poškoduje DNK rakavih celic, jih tako uniči ter prepreči rast in širjenje raka.
Why is Carmustine Obvius authorised in the EU? 
Zakaj je bilo zdravilo Karmustin Obvius odobreno v EU?
Carmustine, the active substance in this medicine, is a type of cancer medicine known as an alkylating agent. 
Karmustin, učinkovina v tem zdravilu, je vrsta zdravila proti raku, znana kot alkilirajoča učinkovina.
For more information about using Carmustine Obvius, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Karmustin Obvius glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Carmustine Obvius are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Karmustin Obvius, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
As for all medicines, data on the use of Carmustine Obvius are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Karmustin Obvius stalno spremljajo.
It must be given under the supervision of a doctor experienced in the use of cancer medicines and can only be obtained with a prescription. 
Dajati se mora pod nadzorom zdravnika z izkušnjami pri uporabi zdravil proti raku, predpisovanje in izdaja zdravila pa je le na recept.
There was no need for ‘bioequivalence' studies to investigate whether Carmustine Obvius is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Izvedba študije bioekvivalence, s katero bi raziskali, ali se zdravilo Karmustin Obvius absorbira podobno kot referenčno zdravilo in tako doseže enake ravni učinkovine v krvi, ni bila potrebna.
Because cancer cells tend to grow and multiply more than normal 
Ker rakave celice bolj rastejo in razmnožujejo kot normalne celice, so bolj dovzetne za delovanje tega zdravila.
This is because Carmustine Obvius is given by infusion into a vein, so the active substance is delivered straight into the bloodstream. 
Zdravilo Karmustin Obvius se namreč daje z infundiranjem v veno, tako da učinkovina vstopa neposredno v krvni obtok.
Carmustine Obvius is given by infusion (drip) into a vein. 
Zdravilo Karmustin Obvius se daje z infundiranjem (kapalno infuzijo) v veno.
Therefore, the Agency's view was that, as for Carmubris, the benefit of Carmustine Obvius outweighs the identified risk and it can be authorised for use in the EU. 
Zato je menila, da koristi zdravila Karmustin Obvius enako kot pri zdravilu Carmubris odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
How has Carmustine Obvius been studied? 
Kako je bilo zdravilo Karmustin Obvius raziskano?
How is Carmustine Obvius used? 
Kako se zdravilo Karmustin Obvius uporablja?
How does Carmustine Obvius work? 
Kako zdravilo Karmustin Obvius deluje?
Date of first authorisation: 26 June 2006 Date of latest renewal: 26 June 2011 
Datum prve odobritve: 26. junij 2006 Datum zadnjega podaljšanja: 26. junij 2011
That expiry date refers to the last day of that month. 
Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
After each use, rinse the spoon with water and allow it to air dry. 
Po vsaki uporabi žličko splaknite z vodo in jo posušite na zraku.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Iron oxide red 
rdeči železov oksid
ULN=upper limit of normal, LLN=lower limit of normal. 
ULN=zgornja meja normalne vrednosti, LLN=spodnja meja normalne vrednosti.
10.7% e 27% e 41.3% e 
10,7% e 27% e 41,3% e 43,6% e a
Baraclude with food and drink 
Zdravilo Baraclude skupaj s hrano in pijačo
In most cases you may take Baraclude with or without food. 
V večini primerov lahko zdravilo Baraclude jemljete skupaj s hrano ali brez nje.
Baraclude reduces the amount of virus in your body, and improves the condition of the liver. 
Zdravilo Baraclude zmanjša količino virusa v telesu in izboljša stanje jeter.
Keep the bottle in the outer carton in order to protect from light. 
Plastenko shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Each carton contains either: 
Vsaka škatla vsebuje:
The measuring spoon is manufactured by: Comar Plastics Division, One Comar Place, Buena, NJ 08310, USA. 
Izdelovalec merilne žličke: Comar Plastics Division, One Comar Place, Buena, NJ 08310, ZDA.
This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodiumfree'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na ml, kar v bistvu pomeni ‘brez natrija'.
Stable or improved CTP scoreb,d MELD score 
Stabilna ali izboljšana ocena po lestvici CTPb,d
Swallow the medicine directly from the measuring spoon. 
Zdravilo pogoltnite neposredno iz merilne žličke.
By 48 weeks of post-treatment follow-up, a substantial number of HBeAg negative patients lost response. 
Pri 48-tedenskem spremljanju po zdravljenju se je pri znatnem števili HBeAg negativnih bolnikov odziv izgubil.
Authorised Representative in the EEA for Comar Plastics: MDSS GmbH, Schiffgraben 41, 30175 Hannover, Germany 
Pooblaščeni zastopnik za Comar Plastics v Evropskem gospodarskem prostoru: MDSS GmbH, Schiffgraben 41, 30175 Hannover, Nemčija.
Some patients must take Baraclude on an empty stomach (see Baraclude with food and drink in Section 2). 
Nekateri bolniki morajo jemati zdravilo Baraclude na prazen želodec (glejte Zdravilo Baraclude skupaj s hrano in pijačo v poglavju 2).
If you forget to take Baraclude 
Če ste pozabili vzeti zdravilo Baraclude
Normalization of:f 
Normalizacija vrednosti:e
Frequency is defined as very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000). 
Pogostnost je definirana kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000).
The on-study cumulative rate of hepatocellular carcinoma (HCC) was 12% (12/102). 
Kumulativni delež pojavnosti hepatocelularnega karcinoma (HCC) med študijo je znašal 12% (12/102).
Hold the spoon in a vertical (upright) position and fill it gradually to the mark corresponding to the prescribed dose. 
Žličko držite navpično (pokonci) in jo počasi napolnite do oznake, ki označuje predpisani odmerek.
Take Baraclude as long as your doctor has told you. 
Zdravilo Baraclude jemljite tako dolgo, kot vam je predpisal zdravnik.
Patients may be dosed with or without food. 
Bolniki lahko odmerek jemljejo s hrano ali brez nje.
A 4 hour period of haemodialysis removed ≈ 13% of the dose, and 0.3% was removed by CAPD. 
Pri 4urni hemodializi se je odstranilo ≈ 13% odmerka, pri CAPD pa 0,3%.
The correct dose of Baraclude oral solution for children and adolescents is calculated by body weight and is taken once daily orally (by mouth) as shown below: 
Pravilen odmerek Baraclude peroralne raztopine za otroke in mladostnike se izračuna na osnovi telesne mase, bolnik pa ga jemlje peroralno (skozi usta) enkrat na dan kot je prikazano v nadaljevanju:
Do not dilute or mix this solution with water or anything else. 
Raztopine ne smete redčiti ali jo mešati z vodo ali s čim drugim.
Children and adolescents (from 2 to less than 18 years of age) can take Baraclude with or without food. 
Otroci in mladostniki (stari od 2 leti do manj kot 18 let) lahko zdravilo Baraclude jemljejo skupaj s hrano ali brez nje.
Baraclude belongs to a class of medicines that can cause lactic acidosis (excess of lactic acid in your blood) and enlargement of the liver. 
zdravilo Baraclude spada v skupino zdravil, ki lahko povzročijo laktacidozo (čezmerno kopičenje mlečne kisline v krvi) in povečanje jeter.
This medicinal product must not be mixed with water, other solvents or other medicinal products. 
Zdravila ne smemo mešati z vodo, drugimi topili ali drugimi zdravili.
Baraclude will not control your HIV infection. 
Zdravilo Baraclude ne more nadzirati okužbe z virusom HIV.
It is important that women of childbearing age receiving treatment with Baraclude use an effective method of contraception to avoid becoming pregnant. 
Pomembno je, da ženske v rodni dobi med zdravljenjem z zdravilom Baraclude za preprečitev nosečnosti uporabljajo učinkovito metodo kontracepcije.
If you miss a dose of Baraclude, take it as soon as possible, and then take your next scheduled dose at its regular time. 
Pozabljeni odmerek zdravila Baraclude vzemite takoj, ko je to mogoče, naslednji odmerek pa nato vzemite ob običajnem času.
Holding the spoon with the volume marks facing you, check that it has been filled to the proper mark. 
Žličko držite tako, da so volumske oznake obrnjene k vam in preverite, da je napolnjena do ustrezne oznake.